IMC Chicago’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $39.4M | Sell |
649,200
-1,100
| -0.2% | -$64.1K | 0.01% | 585 |
|
|
2025
Q4 | $35.1M | Sell |
650,300
-118,000
| -15% | -$5.68M | 0.01% | 612 |
|
|
2025
Q3 | $34.7M | Buy |
768,300
+89,800
| +13% | +$4.19M | 0.01% | 577 |
|
|
2025
Q2 | $31.4M | Buy |
678,500
+15,700
| +2% | +$771K | 0.01% | 531 |
|
|
2025
Q1 | $40.4M | Sell |
662,800
-41,200
| -6% | -$2.4M | 0.02% | 373 |
|
|
2024
Q4 | $39.8M | Sell |
704,000
-221,800
| -24% | -$12.4M | 0.02% | 404 |
|
|
2024
Q3 | $47.9M | Buy |
925,800
+115,800
| +14% | +$5.43M | 0.03% | 313 |
|
|
2024
Q2 | $33.6M | Buy |
810,000
+420,600
| +108% | +$18.8M | 0.02% | 378 |
|
|
2024
Q1 | $21.1M | Sell |
389,400
-27,500
| -7% | -$1.4M | 0.01% | 449 |
|
|
2023
Q4 | $21.4M | Buy |
416,900
+220,800
| +113% | +$11.6M | 0.01% | 439 |
|
|
2023
Q3 | $11.4M | Sell |
196,100
-31,100
| -14% | -$1.91M | 0.01% | 522 |
|
|
2023
Q2 | $14.5M | Buy |
227,200
+14,500
| +7% | +$972K | 0.01% | 427 |
|
|
2023
Q1 | $14.7M | Sell |
212,700
-10,200
| -5% | -$719K | 0.02% | 400 |
|
|
2022
Q4 | $16M | Sell |
222,900
-900
| -0.4% | -$67.9K | 0.03% | 355 |
|
|
2022
Q3 | $15.9M | Buy |
223,800
+38,700
| +21% | +$2.81M | 0.02% | 348 |
|
|
2022
Q2 | $14.3M | Sell |
185,100
-40,300
| -18% | -$3.07M | 0.02% | 359 |
|
|
2022
Q1 | $16.5M | Sell |
225,400
-67,200
| -23% | -$4.51M | 0.02% | 369 |
|
|
2021
Q4 | $18.2M | Buy |
292,600
+133,600
| +84% | +$7.84M | 0.02% | 379 |
|
|
2021
Q3 | $9.41M | Buy |
159,000
+21,000
| +15% | +$1.38M | 0.01% | 501 |
|
|
2021
Q2 | $9.22M | Sell |
138,000
-15,100
| -10% | -$985K | 0.01% | 469 |
|
|
2021
Q1 | $9.66M | Buy |
153,100
+30,600
| +25% | +$1.9M | 0.01% | 433 |
|
|
2020
Q4 | $7.6M | Sell |
122,500
-1,400
| -1% | -$86.1K | 0.01% | 461 |
|
|
2020
Q3 | $7.47M | Sell |
123,900
-17,000
| -12% | -$1.02M | 0.01% | 358 |
|
|
2020
Q2 | $8.29M | Buy |
140,900
+34,300
| +32% | +$2.05M | 0.02% | 290 |
|
|
2020
Q1 | $5.94M | Sell |
106,600
-21,800
| -17% | -$1.33M | 0.01% | 295 |
|
|
2019
Q4 | $8.24M | Sell |
128,400
-56,900
| -31% | -$3.26M | 0.02% | 251 |
|
|
2019
Q3 | $9.4M | Sell |
185,300
-300
| -0.2% | -$14.1K | 0.03% | 187 |
|
|
2019
Q2 | $8.42M | Sell |
185,600
-53,300
| -22% | -$2.48M | 0.03% | 198 |
|
|
2019
Q1 | $11.4M | Buy |
238,900
+168,500
| +239% | +$8.39M | 0.04% | 127 |
|
|
2018
Q4 | $3.66M | Buy |
+70,400
| New | +$3.78M | 0.01% | 254 |
|
Other funds holding BMY
VCM
VPM
IMC Chicago's BMY Position: Q1 2026 in Review
IMC Chicago sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 45,935 shares — an estimated $2.68M sold.
IMC Chicago first reported a position in BMY in Q2 2019 and held it in 7 quarters. The position peaked at $15.8M in Q4 2019. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- IMC Chicago reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
- IMC Chicago sold 45,935 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.68M.
- IMC Chicago first reported a position in Bristol-Myers Squibb in Q2 2019 and held it in 7 quarters.
- IMC Chicago's Bristol-Myers Squibb position peaked at $15.8M in Q4 2019.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.